HCC

Warrior Met Coal, Inc.

$81.28

-$3.58 (-4.22%)Today

+$0.00 (+0.00%)After Hours

Key Statistics

Market cap4.29B

Price-Earnings ratio31.14

Dividend yield0.38%

Average volume847.4K

High today$86.08

Low today$80.02

Open price$84.01

Volume842.81K

52 Week high$110.39

52 Week low$43.43

Company Profile

Description

Warrior Met Coal, Inc. engages in the production and export of non-thermal steelmaking coal for the steel production by metal manufacturers in Europe, South America, and Asia. It offers hard-coking coal through the operation of underground mines located in Alabama. The company also sells natural gas extracted as a byproduct from coal production. Warrior Met Coal, Inc. was incorporated in 2015 and is headquartered in Brookwood, Alabama.

Sector

Basic Materials

Industry

Coking Coal

CEO

Mr. Walter J. Scheller III

Website

warriormetcoal.com

Company Profile

Description

Sector

Basic Materials

Industry

Coking Coal

CEO

Mr. Walter J. Scheller III

Website

warriormetcoal.com

HCC

Key Statistics

Company Profile

Company Profile

Recent News

Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology

Third Avenue Value Fund's Strategic Moves: Harley-Davidson Inc. Takes Center Stage

Accuity Names Gary Basra Chief Technology Officer to Scale the Platform Behind Its Physician-Governed AI

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

Recent News

Company Profile

Recent News

Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology

Third Avenue Value Fund's Strategic Moves: Harley-Davidson Inc. Takes Center Stage

Accuity Names Gary Basra Chief Technology Officer to Scale the Platform Behind Its Physician-Governed AI

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

Here is Why BeOne (ONC) One of the Most Promising Long-Term Stocks to Buy According to Analysts

Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson

Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026